通宣理肺颗粒联合头孢丙烯治疗小儿急性上呼吸道感染的临床研究

目的 探讨通宣理肺颗粒联合头孢丙烯治疗小儿急性上呼吸道感染的临床疗效。方法 选取2021年1月—2022年10月广西中医药大学第一附属医院收治的226例急性上呼吸道感染患儿，按随机数字表法将所有患儿分为对照组和治疗组，每组各113例。对照组口服头孢丙烯颗粒，每次7.5 mg/kg，2次/d。治疗组在对照组基础上口服通宣理肺颗粒，1～3岁1/3袋/次；4～6岁1/2袋/次；7岁以上1袋/次；2次/d。两组疗程均为5 d。观察两组临床疗效、主要表现消失时间，比较治疗前后两组儿童睡眠习惯问卷（CSHQ）评分、儿少心理健康量表（MHS-CA）评分、儿童生活质量量表4.0（Peds QLTM4.0）评分及全血白细胞计数（WBC）、中性粒细胞比例（NEUT%）、C反应蛋白（CRP）、降钙素原（PCT）水平。结果 治疗后，治疗组总有效率为96.46%，显著高于对照组的88.50%（P＜0.05）。治疗组发热、咳嗽、咽痛、鼻塞、流涕消失时间均较对照组显著更短（P＜0.05）。治疗后，两组CSHQ评分均显著降低，而MHS-CA、Peds QLTM4.0评分均显著增高（P＜0.05）；且治疗后，CSHQ、MHS-CA、Peds QLTM4.0评分均以治疗组改善更显著（P＜0.05）。治疗后，两组全血WBC、NEUT%、CRP、PCT水平均显著下降（P＜0.05）；且治疗后，治疗组WBC、NEUT%、CRP、PCT水平低于对照组（P＜0.05）。结论 通宣理肺颗粒联合头孢丙烯治疗小儿急性上呼吸道感染具有较好的临床疗效，能有效加速患儿主要临床表现的消失，抑制机体感染及炎症状态，使睡眠、心理及生活质量得到有效改善，值得临床推广应用。

Clinical study of Tongxuan Lifei Granules combined with cefprozil in treatment of children with acute upper respiratory tract infection

Objective To explore the clinical efficacy of Tongxuan Lifei Granules combined with cefprozil in treatment of children with acute upper respiratory tract infection. Methods A total of 226 children with acute upper respiratory tract infection admitted to the First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine from January 2021 to October 2022 were selected and divided into control group and treatment group according to random number table method, with 113 cases in each group. Patients in control group were po administered with Cefprozil Granules, 7.5 mg/kg each time, twice daily. Patients in the treatment group were po administered with Tongxuan Lifei Granules on the basis of the control group, 1 — 3 years old 1/3 bag/time; 4 — 6 years old 1/2 bag/time; over 7 years old 1 bag/time; twice daily. The treatment course of both groups was 5 d. The clinical efficacy and disappearance time of main manifestations were observed in the two groups. The Sleep Habits Questionnaire (CSHQ) scores, Children’s Mental Health Scale (MHS-CA) scores, and Children’s Quality of Life Scale 4.0 (Peds QLTM4.0) scores, whole blood white blood cell count (WBC), neutrophil ratio (NEUT%), C-reactive protein (CRP), and procalcitonin (PCT) were compared between two groups before and after treatment. Results After treatment, the total effective rate of treatment group was 96.46%, which was significantly higher than that of control group (88.50%, P＜0.05). The disappearance time offever, cough, sore throat, stuffy nose, and runny nose in treatment group was significantly shorter than that in control group (P＜0.05). After treatment, CSHQ scores were significantly decreased in both groups, but MHS-CA and Peds QLTM4.0 scores were significantly increased (P＜0.05). After treatment, CSHQ, MHS-CA and Peds QLTM4.0 scores were significantly improved in treatment group (P＜0.05). After treatment, whole blood WBC, NEUT%, CRP, and PCT levels were significantly decreased in both groups (P＜ 0.05). After treatment, the levels of WBC, NEUT%, CRP, and PCT in treatment group were lower than those in control group (P＜0.05). Conclusion Tongxuan Lifei Granules combined with cefprozil has good clinical efficacy in treatment of children with acute upper respiratory tract infection, and can effectively accelerate the disappearance of the main clinical manifestations of children, inhibit the infection and inflammation of the body, and effectively improve the sleep, psychology and quality of life, which is worthy of clinical promotion and application.